JWH-018

---

title: "JWH-018" type: doc version: 1 created: 2026-02-28 author: "Wikipedia contributors" status: active scope: public tags: ["designer-drugs", "euphoriants", "jwh-cannabinoids", "naphthoylindoles", "cb1-receptor-agonists", "cb2-receptor-agonists", "pentyl-compounds"] description: "Chemical compound" topic_path: "general/designer-drugs" source: "https://en.wikipedia.org/wiki/JWH-018" license: "CC BY-SA 4.0" wikipedia_page_id: 0 wikipedia_revision_id: 0

::summary Chemical compound ::

| Verifiedfields = changed | class = Cannabinoid | verifiedrevid = 477168756 | IUPAC_name = (Naphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone | image = JWH018.svg | image_class = skin-invert-image | image2 = JWH-018 ball-and-stick model.png | image_class2 = bg-transparent

| legal_AU = S9 | legal_BR = F2 | legal_BR_comment = | legal_UK = Class B | legal_US = Schedule I | legal_DE = Anlage II | legal_CA = Schedule II, In general uncontrolled could be illegal to sell for human consumption or the analogue acts in several countries. | legal_UN = P II | legal_UN_comment = | routes_of_administration = {{plainlist|

• By mouth,
• inhalation}}

| CAS_number_Ref = | elimination_half-life = {{plainlist|

• Inhalation:
• 1.69 hours}} | CAS_number = 209414-07-3 | UNII_Ref = | UNII = G391998J57 | ATC_prefix = None | PubChem = 10382701 | DrugBank_Ref = | ChemSpiderID_Ref = | ChemSpiderID = 8558143 | ChEMBL_Ref = | ChEMBL = 561013 | KEGG_Ref = | KEGG = C22748

| C = 24 | H = 23 | N = 1 | O = 1 | SMILES = CCCCCN1C=C(C(C2=CC=CC3=CC=CC=C32)=O)C4=CC=CC=C41 | StdInChI_Ref = | StdInChI = 1S/C24H23NO/c1-2-3-8-16-25-17-22(20-13-6-7-15-23(20)25)24(26)21-14-9-11-18-10-4-5-12-19(18)21/h4-7,9-15,17H,2-3,8,16H2,1H3 | StdInChIKey_Ref = | StdInChIKey = JDNLPKCAXICMBW-UHFFFAOYSA-N | solubility = hydrophobic, n/a JWH-018 (1-pentyl-3-(1-naphthoyl)indole, NA-PIMO or AM-678) is an analgesic chemical from the naphthoylindole family that acts as a full agonist at both the CB1 and CB2 cannabinoid receptors, with some selectivity for CB2. It produces effects in animals similar to those of tetrahydrocannabinol (THC), a cannabinoid naturally present in cannabis, leading to its use as synthetic cannabinoid products that, in some countries, are sold legally as "incense blends".

As a full agonist at both the CB1 and CB2 cannabinoid receptors, this chemical compound is classified as an analgesic medication. The analgesic effects of cannabinoid ligands, mediated by CB1 receptors are well established in treatment of neuropathic pain, as well as cancer pain and arthritis.

These compounds work by mimicking the body's naturally-produced endocannabinoid hormones such as 2-AG and anandamide (AEA), which are biologically active and can exacerbate or inhibit nerve signaling. As the cause is poorly understood in chronic pain states, more research and development must be done before the therapeutic potential of this class of biologic compounds can be realized.

History

John W. Huffman, an organic chemist at Clemson University, synthesized a variety of chemical compounds that affect the endocannabinoid system. JWH-018 is one of these compounds, with studies showing an affinity for the cannabinoid CB1 receptor five times greater than that of THC.

On 15 December 2008, it was reported by German pharmaceutical companies that JWH-018 was found as one of the active components in at least three versions of the grey market drug Spice, which has been sold as an incense in a number of countries around the world since 2006. An analysis of samples acquired four weeks after the German prohibition of JWH-018 took place found that the manufacturers had shortened the alkyl chain by one carbon to circumvent the ban.

Pharmacology

JWH-018 is a full agonist of both the CB1 and CB2 cannabinoid receptors, with a reported binding affinity of 9.00 ± 5.00 nM at CB1 and 2.94 ± 2.65 nM at CB2. JWH-018 has an EC50 of 102 nM for human CB1 receptors, and 133 nM for human CB2 receptors. JWH-018 produces bradycardia and hypothermia in rats at doses of 0.3–3 mg/kg, suggesting potent cannabinoid-like activity. In synthetic cannabinoids, the switch to being a full agonist, increases the activation towards extending its psychoactivity and not regulating but also extending central nervous-activity anymore, to be more selective (CB1). This is meaning an activation of the central nervous system. Therefore, indirectly activating dopaminerelease in the cortexareas of the frontal brain. This is meaning, that it is activating and so, is being dopaminerg. Therefore, it can induce potent dopaminergic and hypnotic states with JWH-018 being heavy sedative with a binding affinity of 9.0 KnM.

Primary signalchannels at the cannabinoidreceptor CB1 in the central nervous system are occupated and are getting excessively activated by its agonism with 9nM nanomolar affinity.

So, it can induce a potent inhibition on ones capapillity to coordinate movement.

Pharmacokinetics

Metabolism of JWH-018 was assessed using Wistar rats which had been administered an ethanolic extract containing JWH-018. Urine was collected for 24 hours, followed by extraction of JWH-018 metabolites using both liquid-liquid extraction and solid-phase extraction. GC-MS was utilized to separate and identify the extracted compounds. JWH-018 and its N-dealkylated metabolite were only detected in small amounts, with hydroxylated N-dealkylated metabolites comprising the primary signal. The observed mass shift indicates that it is likely that hydroxylation occurs in both the naphthalene and indole portions of the molecule. Human metabolites were similar although most metabolism took place on the indole ring and pentyl side chain, and the hydroxylated metabolites were extensively conjugated with glucuronide. When inhaled, the median half-life of JWH-018 is 1.69 hours.

Recreational use

At least one case of JWH-018 dependence has been reported by the media. The user consumed JWH-018 daily for eight months. Withdrawal symptoms were more severe than those experienced as a result of cannabis dependence. JWH-018 has been shown to cause profound changes in CB1 receptor density following administration, causing desensitization to its effects more rapidly than related cannabinoids.

On 15 October 2011, Anderson County coroner Greg Shore attributed the death of a South Carolina college basketball player to "drug toxicity and organ failure" caused by JWH-018. A November 2011 email concerning the case was released in December 2011 under the Freedom of Information Act after multiple requests to see the information had been denied.

Compared to THC, which is a partial agonist at CB1 receptors, JWH-018, and many synthetic cannabinoids, are full agonists. JWH-018 may cause intense anxiety, agitation, and in rare cases, has been assumed to have been the cause of seizures and convulsions. JWH-018 and analogs of it may present serious dangers to the user when used to excess.

Various physical and psychological adverse effects have been reported from JWH-018 use. One study reported psychotic relapses and anxiety symptoms in well-treated patients with mental illness following JWH-018 inhalation. Due to concerns about the potential of JWH-018 and other synthetic cannabinoids to cause psychosis in vulnerable individuals, it has been recommended that people with risk factors for psychotic disorders, such as a past or family history of psychosis, not use these substances.

Detection in biological fluids

JWH-018 usage is readily detected in urine using "spice" screening immunoassays from several manufacturers focused on both the parent drug and its omega-hydroxy and carboxyl metabolites. JWH-018 will not be detected by older methods employed for detecting THC and other cannabis terpenoids. Determination of the parent drug in serum or its metabolites in urine has been accomplished by GC-MS or LC-MS. Serum JWH-018 concentrations are generally in the 1–10 μg/L range during the first few hours after recreational usage. The major urinary metabolite is a compound that is monohydroxylated on the omega minus one carbon atom of the alkyl side chain. A lesser metabolite monohydroxylated on the omega (terminal) position was present in the urine of six users of the drug at concentrations of 6–50 μg/L, primarily as a glucuronide conjugate.

Legal status

::figure[src="https://upload.wikimedia.org/wikipedia/commons/7/7a/JWH-018.jpg" caption="JWH-018 powder as it was commonly sold online"] ::

::data[format=table]

Country	Date of ban	Notes
Austria	18 December 2008	The Austrian Ministry of Health announced on 18 December 2008 that Spice would be controlled under Paragraph 78 of their drug law on the grounds that it contains an active substance that affects the functions of the body, and the legality of JWH-018 is under review.
Australia	9 September 2011	JWH-018 is considered a Schedule 9 prohibited substance in Australia under the Poisons Standard (October 2015). A Schedule 9 substance is a substance which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities.
Belarus	1 January 2010
Canada	21 February 2012	Despite the Canadian federal government having officially legalized the recreational use of cannabis on October17, 2018 , substances such as JWH-018 and JWH-073 are both on the most recently amended Schedule II of the Controlled Drugs and Substances Act.Schedule. (Sections 2, 4 to 7.1, 10, 29, 55 and 60)
China	1 January 2012	China has made JWH-018 Illegal for sale. It is illegal to import or export JWH-018.
Estonia	24 July 2009
Finland	12 March 2012	Illegal
France	24 February 2009	url=http://www.emcdda.europa.eu/publications/drug-profiles/synthetic-cannabinoids#control
Germany	22 January 2009
Ireland	11 May 2010	url = http://www.irishtimes.com/newspaper/breaking/2010/0511/breaking41.html
Italy	2 July 2010
Japan	3 August 2012	{{cite web
Jordan	2 September 2014	The Anti-narcotics department declared synthetic cannabinoids and their analogues illegal after an outbreak of JWH-018 containing product referred to as "Joker".
Latvia	28 November 2009
New Zealand	8 May 2014
Norway	21 December 2011
Poland	8 May 2009
Romania	15 February 2010
Russia	22 January 2010
South Korea	1 July 2009
Sweden	30 July 2009	A bill to ban JWH-018 was accepted on 30 July 2009 and was in effect on 15 September 2009.
Turkey	13 February 2011	Turkish authorities were first informed about JWH-018 through the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). The seizure of 2C-B in blue pill form on 13 October 2010 and the seizure of 0.6 g JWH-018 on 16 April 2010 in Eskisehir was reported through the Early Warning System (EWS). Upon these reports the EWS committee initiated the regulation process by warning the Ministry of Health. In response to the official letter #86106 issued by the Ministry of Health dated 22 December 2010, the Council of Ministers decided on 7 January 2011 to add 14 cannabinoids; namely JWH-018, CP 47,497, JWH-073, HU-210, JWH-200, JWH-250, JWH-398, JWH-081, JWH-073, JWH-015, JWH-122, JWH-203, JWH-210, JWH-019; phenethylamines 2C-B and 2C-P as well as Catha edulis to the list of substances subject to the Law on Control of Narcotic Drugs. The regulation is in effect since 13 February 2011. Upon letter #12099 issued by the Ministry of Health dated 6 February 2012, 4 more cannabinoids (AM-2201, RCS-4, JWH-201 and JWH-302), Salvia divinorum and several other chemicals (complete list here ) were added to the list of controlled substances on 17 February 2012 which is effective since 22 March 2012.
Ukraine	31 May 2010
United Kingdom	23 December 2009
United States	1 March 2011	JWH-018 was temporarily scheduled on 1 March 2011 by 76 FR 11075. It was permanently scheduled on 9 July 2012 by Section 1152 of the Food and Drug Administration Safety and Innovation Act (FDASIA)
::

Synthesis

::figure[src="https://upload.wikimedia.org/wikipedia/commons/9/96/JWH-018_synthesis.svg" caption="pmid = 24823967 }}"] ::

References

References

1. (2023-07-24). "RDC Nº 804 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial". Brazilian Health Regulatory Agency.
2. "Substance Details JWH-018".
3. (March 2023). "EMCDDA framework and practical guidance for naming synthetic cannabinoids". Drug Testing and Analysis.
4. (2011-03-01). "Department of Justice :: Drug Enforcement Administration".
5. (2009). "Withdrawal Phenomena and Dependence Syndrome After the Consumption of "Spice Gold"". Dtsch Ärztebl Int.
6. (2000). "Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB₁ and CB₂ receptor binding". Drug and Alcohol Dependence.
7. "Cannabimimetic indole derivatives".
8. "Cannabimimetic indole derivatives".
9. (June 2010). "JWH018, a common constituent of 'Spice' herbal blends, is a potent and efficacious cannabinoid CB receptor agonist". British Journal of Pharmacology.
10. (December 2012). "Dynamic changes to the endocannabinoid system in models of chronic pain". Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences.
11. "Clemson University :: Department of Chemistry". Clemson.edu.
12. "Gefährlicher Kick mit Spice".
13. "Erstmals Bestandteile der Modedroge "Spice" nachgewiesen".
14. (15 December 2008). "Spice enthält chemischen Wirkstoff".
15. (2009). "Spice: A never ending story?". Forensic Science International.
16. (August 2015). "Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135". ACS Chemical Neuroscience.
17. "Agonist".
18. (2015). "The Therapeutic Potential of Cannabinoids for Movement Disorders". Movement Disorders : Official Journal of the Movement Disorder Society.
19. (2009). "Studies on the metabolism of JWH-018, the pharmacologically active ingredient of different misused incenses.". Toxichem+ Krimtech.
20. (July 2010). "Detection of JWH-018 metabolites in smoking mixture post-administration urine". Forensic Science International.
21. (April 2018). "Pharmacokinetic properties of the synthetic cannabinoid JWH-018 in oral fluid after inhalation". Drug Testing and Analysis.
22. (14 October 2011). "Coroner: Synthetic Pot Killed College Athlete". wyff4.com.
23. (16 December 2011). "City Releases Email in Lamar Jacks Case". independentmail.com.
24. (2009). "Understanding the Spice Phenomenon". European Monitoring Centre for Drugs and Drug Addiction..
25. (September 2011). "Synthetic cannabinoid JWH-018 and psychosis: an explorative study". Drug and Alcohol Dependence.
26. (October 2010). "Warning: legal synthetic cannabinoid-receptor agonists such as JWH-018 may precipitate psychosis in vulnerable individuals". Addiction.
27. (June 2013). "Validation of a novel immunoassay for the detection of synthetic cannabinoids and metabolites in urine specimens". Journal of Analytical Toxicology.
28. Möller I, ''et al.'' Screening for the synthetic cannabinoid JWH-018 and its major metabolites in human doping controls. Drug Test. Anal. 24 Sep 2010. [Epub ahead of print]
29. Teske J, ''et al.'' Sensitive and rapid quantification of the cannabinoid receptor agonist naphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-018) in human serum by liquid chromatography-tandem mass spectrometry. J Chrom. B 878: 2659-2663, 2010.
30. (2009). "'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs?". Journal of Mass Spectrometry.
31. (2009). "Withdrawal phenomena and dependence syndrome after the consumption of "spice gold"". Deutsches Ärzteblatt International.
32. (2010). "Detection of JWH-018 metabolites in smoking mixture post-administration urine". Forensic Science International.
33. (August 2011). "Structure characterisation of urinary metabolites of the cannabimimetic JWH-018 using chemically synthesised reference material for the support of LC-MS/MS-based drug testing". Anal Bioanal Chem.
34. (June 2011). "Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine". Anal. Chem..
35. Logan BK, ''et al.'' Identification of primary JWH-018 and JWH-073 metabolites in human urine. NMS Labs Technical Bulletin, 25 May 2011. http://toxwiki.wikispaces.com/file/view/JWH_metabolites_Technical_Bulletin_Final_v1.1.pdf
36. R. Baselt, ''Disposition of Toxic Drugs and Chemicals in Man'', 10th edition, Biomedical Publications, Seal Beach, CA, 2014, p. 1863.
37. [https://www.comlaw.gov.au/Details/F2015L01534 Poisons Standard] comlaw.gov.au October 2015
38. (11 May 2021). "China issues total ban on synthetic cannabinoids".
39. "Tiedote/Valtioneuvoston viestintäyksikkö: VALTIONEUVOSTON YLEISISTUNTO 1.3.2012".
40. "FINLEX - Ajantasainen lainsäädäntö: Valtioneuvoston asetus huumausaineina... 543/2008".
41. "FINLEX - Ajantasainen lainsäädäntö: Valtioneuvoston asetus kuluttajamarkkinoilta... 1130/2014".
42. "Arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants". Agence française de sécurité sanitaire des produits de santé (AFSSAPS) French agency for the safety of health products.
43. [http://www.bgblportal.de/BGBL/bgbl1f/bgbl109s0049.pdf BGBl I Nr. 3 vom 21.01.2009, 22. BtMÄndV vom 19. Januar 2009, S. 49–50].
44. "Many head shop products banned". Irish Times.
45. "Spice, N-joy e mefedrone da oggi stupefacenti". politicheantidroga.it.
46. link. (29 June 2012). [[Ministry of Health, Labour, and Welfare. MHLW]]
47. "Anti-narcotics".
48. "Latvian list of prohibited drugs".
49. "What they are".
50. "Forskrift om endring i forskrift om narkotika m.v. (Narkotikalisten)".
51. (2 July 2009). "1일부터 '5-메오-밉트' 등 향정신성의약품 지정". hkn24.com.
52. "Regeringen förbjuder nätdrogen "Spice"".
53. "Illicit Drug Report of Turkey 2010". Department of Anti-smuggling and Organised Crime.
54. "Decision of the Council of Ministers, Enactment 2011/1310". General Directorate of Legislation Development and Publication.
55. "Attachment to Enactment 2012/2861". General Directorate of Legislation Development and Publication.
56. "Decision of the Council of Ministers, Enactment 2012/2861". General Directorate of Legislation Development and Publication.
57. (2009-12-23). "Three legal highs banned after deaths linked to the drugs". The Times.
58. "Schedules of Controlled Substances: Temporary Placement of Four Synthetic Cannabinoids Into Schedule I". DEA Office of Diversion Control.
59. (2014). "Recreational drug discovery: natural products as lead structures for the synthesis of smart drugs". Natural Product Reports.

::callout[type=info title="Wikipedia Source"] This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page. ::